Photo of Tom Powles taken from bartscancer.london
May 28, 2024, 14:33
Tom Powles: Final results for axitinib/avelumab in 1st line RCC at ASCO24
Tom Powles, Director of Barts Cancer Center, shared on X:
“Final results for axitinib/avelumab in 1st line RCC at ASCO24.
It wasn’t initially backed due to no significant OS (unlike PD1 combos). .
HRs for the PD-1 combos have drifted (0.5s to 0.7s) but remain significant, unlike axi/avelumab (OS HR0.88). PD1 combos remain the stand of care.”
Source: Tom Powles/X